Treatment of Palmar Plantar Erythrodysesthesia (PPE) With Topical Sildenafil
| Status: | Archived |
|---|---|
| Conditions: | Cancer |
| Therapuetic Areas: | Oncology |
| Healthy: | No |
| Age Range: | Any |
| Updated: | 7/1/2011 |
| Start Date: | June 2010 |
| End Date: | September 2012 |
Hand-foot syndrome (HFS), also known as palmar-plantar erythrodysethesia (PPE), occurs in a
25%-50% of patients treated with several commonly used anti-cancer drugs including
capecitabine and sunitinib. These drugs are known to improve survival in many cancers,
including cancers of the colon, stomach, liver, breast, kidney, and GI stromal tumors
(GIST). Worldwide, over 400,000 patients per year are treated with one of these agents. HFS
involves skin changes, such as swelling, peeling, and blistering of the palms and soles,
which is often painful and debilitating. As a result, HFS-related symptoms can frequently
lead to dose reduction and/or discontinuation of otherwise effective anti-cancer treatment.
There is no treatment for HFS other than dose reduction or stopping treatment. This
proposal could quickly lead to treatments to prevent and/or treat HFS and help patients
avoid debilitating side effects while continuing otherwise effective treatments for their
cancer.
The primary objective is to evaluate whether topical sildenafil reduces the severity of hand
foot syndrome or palmar plantar erythrodysesthesia (PPE) associated with sunitinib and
capecitabine. The secondary objective is to describe any toxicities associated with topical
sildenafil.
This is a randomized, double blind, placebo-controlled pilot study of topical sildenafil for
patients with grade 1-3 hand foot syndrome related to chemotherapeutic agents.
Approximately 20 evaluable patients with grade 1-3 PPE will be treated with topical
sildenafil:
- 10 patients with PPE related to sunitinib
- 10 patients with PPE related to capecitabine
Once eligibility and screening criteria are met, subjects will be given 2 types of topical
cream, one containing 1% sildenafil citrate and one containing placebo control. Subjects
will be randomized to apply sildenafil citrate cream to either the right or left hand/foot;
placebo cream will be applied to the opposite hand/ foot.
Clinical history, physical examination and photography of the hands and feet will be
performed every two weeks for the first 2 months for patients on sunitinib and then every
4-6 weeks thereafter. For patients on capecitabine (which is given on an every 3 week
schedule), these evaluations will be done every 3 weeks. Additional visits may be performed
if clinically indicated.
If PPE resolves, less frequent administration and lower doses will be permitted to maintain
responses. For consistency, patients may first reduce treatment to twice per day at the
dose at which the PPE resolved. If this dosing schedule is effective then lower
concentrations, e.g. 0.5%, may be used.
Patient cream assignment will be un-blinded at the 8 or 9 week time period (depending on the
chemotherapy). However, patients with a 2 grade improvement in PPE in one hand versus the
other (e.g. grade 3 improves to grade 1, or grade 2 improves to grade 0) that is maintained
for at least 2 weeks, will be eligible for early un-blinding and treatment with active
sildenafil for both hands and both feet.
Patients may receive topical sildenafil for up to 6 months on study.
We found this trial at
1
site
Duke Univ Med Ctr As a world-class academic and health care system, Duke Medicine strives...
Click here to add this to my saved trials
